Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 4Thyroid Cancer, Papillary 1Neoplasm Metastasis 1Differentiated Thyroid Carcinoma 1Adenocarcinoma, Follicular 1

Interventions

Magnetic Resonance Spectroscopy 5trametinib 4Vemurafenib 4selpercatinib 3dabrafenib 3Specimen Handling 3entrectinib 2cobimetinib 2cabozantinib 2X-Rays 2Iodine-131 2Interviews as Topic 2tremelimumab 1tovorafenib 1spartalizumab 1pembrolizumab 1omipalisib 1lenvatinib 1gallium Ga 68 dotatate 1durvalumab 1copanlisib 1Whole Body Imaging 1Transurethral Resection of Prostate 1Thyrotropin Alfa 1Surveys and Questionnaires 1Sodium Iodide 1Robotic Surgical Procedures 1Postoperative Period 1Phantoms, Imaging 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Cancer, Papillary × Iodine-124 × 1 year × Clear all
NCT02152995 2026-04-13

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
34 enrolled 18 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡